服用Semaglutide 2.4 mg并加入数字自我支持应用程序WeGoTogether的患者的真实体重减轻

IF 4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2025-08-06 DOI:10.1007/s12325-025-03325-1

Joshua C. Toliver, Victoria Divino, Carmen D. Ng, Julia Wang

{"title":"服用Semaglutide 2.4 mg并加入数字自我支持应用程序WeGoTogether的患者的真实体重减轻","authors":"Joshua C. Toliver, Victoria Divino, Carmen D. Ng, Julia Wang","doi":"10.1007/s12325-025-03325-1","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Semaglutide injection 2.4 mg (Wegovy<sup>®</sup>; hereafter referred to as semaglutide) was approved by the US Food and Drug Administration in June 2021 for chronic weight management in adults with overweight or obesity. This study aimed to evaluate the real-world long-term effectiveness of semaglutide in combination with the WeGoTogether patient support program with a follow-up period of up to 24 months.</p><h3>Methods</h3><p>This retrospective, noninterventional cohort study included adults with overweight or obesity (body mass index [BMI] ≥ 25.0 kg/m<sup>2</sup>) who initiated semaglutide and enrolled in WeGoTogether during the study period (6/2021–4/2025). Semaglutide is administered as a once-weekly subcutaneous injection. Patients had ≥ 2 post-index weights, with ≥ 1 weight at 6, 12, 18, and/or 24 months (± 30 days) of follow-up. Self-reported, de-identified data from WeGoTogether were analyzed descriptively. Patient demographics were characterized, and changes in weight and BMI were compared from index to each follow-up time point.</p><h3>Results</h3><p>Overall, 8177 patients met the eligibility criteria, including 7604 (93.0%) patients with a BMI ≥ 30.0 kg/m<sup>2</sup>. At baseline, the mean age was 49.5 years, mean weight was 234.1 lb, and mean BMI was 38.4 kg/m<sup>2</sup>; 83.6% of patients were female. Among patients with reported weight at the time points of interest, the mean (standard deviation) percent weight loss was − 13.4% (6.4) at 6 months (<i>n</i> = 6964), − 17.6% (10.2) at 12 months (<i>n</i> = 2050), − 20.3% (11.4) at 18 months (<i>n</i> = 491), and − 20.4% (11.3) at 24 months (<i>n</i> = 325). The proportions of patients achieving ≥ 20% weight loss were 13.1%, 43.3%, 52.5%, and 50.5% at 6, 12, 18, and 24 months, respectively. Similar results were observed for the subgroup with BMI ≥ 30.0 kg/m<sup>2</sup>.</p><h3>Conclusion</h3><p>The study demonstrated substantial weight loss with semaglutide treatment, including over long-term 18- and 24-month follow-up periods, as reported in the WeGoTogether program. These data suggest patients can achieve clinically meaningful long-term (24 months) weight loss in real-world settings when treated with semaglutide and participating in the WeGoTogether patient support program.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 10","pages":"5010 - 5022"},"PeriodicalIF":4.0000,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03325-1.pdf","citationCount":"0","resultStr":"{\"title\":\"Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application\",\"authors\":\"Joshua C. Toliver, Victoria Divino, Carmen D. Ng, Julia Wang\",\"doi\":\"10.1007/s12325-025-03325-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Semaglutide injection 2.4 mg (Wegovy<sup>®</sup>; hereafter referred to as semaglutide) was approved by the US Food and Drug Administration in June 2021 for chronic weight management in adults with overweight or obesity. This study aimed to evaluate the real-world long-term effectiveness of semaglutide in combination with the WeGoTogether patient support program with a follow-up period of up to 24 months.</p><h3>Methods</h3><p>This retrospective, noninterventional cohort study included adults with overweight or obesity (body mass index [BMI] ≥ 25.0 kg/m<sup>2</sup>) who initiated semaglutide and enrolled in WeGoTogether during the study period (6/2021–4/2025). Semaglutide is administered as a once-weekly subcutaneous injection. Patients had ≥ 2 post-index weights, with ≥ 1 weight at 6, 12, 18, and/or 24 months (± 30 days) of follow-up. Self-reported, de-identified data from WeGoTogether were analyzed descriptively. Patient demographics were characterized, and changes in weight and BMI were compared from index to each follow-up time point.</p><h3>Results</h3><p>Overall, 8177 patients met the eligibility criteria, including 7604 (93.0%) patients with a BMI ≥ 30.0 kg/m<sup>2</sup>. At baseline, the mean age was 49.5 years, mean weight was 234.1 lb, and mean BMI was 38.4 kg/m<sup>2</sup>; 83.6% of patients were female. Among patients with reported weight at the time points of interest, the mean (standard deviation) percent weight loss was − 13.4% (6.4) at 6 months (<i>n</i> = 6964), − 17.6% (10.2) at 12 months (<i>n</i> = 2050), − 20.3% (11.4) at 18 months (<i>n</i> = 491), and − 20.4% (11.3) at 24 months (<i>n</i> = 325). The proportions of patients achieving ≥ 20% weight loss were 13.1%, 43.3%, 52.5%, and 50.5% at 6, 12, 18, and 24 months, respectively. Similar results were observed for the subgroup with BMI ≥ 30.0 kg/m<sup>2</sup>.</p><h3>Conclusion</h3><p>The study demonstrated substantial weight loss with semaglutide treatment, including over long-term 18- and 24-month follow-up periods, as reported in the WeGoTogether program. These data suggest patients can achieve clinically meaningful long-term (24 months) weight loss in real-world settings when treated with semaglutide and participating in the WeGoTogether patient support program.</p></div>\",\"PeriodicalId\":7482,\"journal\":{\"name\":\"Advances in Therapy\",\"volume\":\"42 10\",\"pages\":\"5010 - 5022\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-08-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s12325-025-03325-1.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s12325-025-03325-1\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-025-03325-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

介绍：Semaglutide注射液2.4 mg (Wegovy®；以下简称semaglutide)于2021年6月获得美国食品和药物管理局（fda）批准，用于超重或肥胖成人的慢性体重管理。本研究旨在评估西马鲁肽与WeGoTogether患者支持计划联合使用的实际长期有效性，随访期长达24个月。方法：这项回顾性、非介入性队列研究纳入了超重或肥胖（体重指数[BMI]≥25.0 kg/m2）的成年人，他们在研究期间（6/2021-4/2025）开始使用西马鲁肽并加入了WeGoTogether。西马鲁肽每周皮下注射一次。患者指数后体重≥2，随访6、12、18和/或24个月（±30天）时体重≥1。对来自WeGoTogether的自我报告、去识别数据进行描述性分析。对患者的人口统计学特征进行描述，并比较从指数到每个随访时间点的体重和BMI变化。结果：总体而言，8177例患者符合入选标准，其中7604例（93.0%）患者BMI≥30.0 kg/m2。基线时，平均年龄49.5岁，平均体重234.1 lb，平均BMI为38.4 kg/m2；83.6%为女性。在感兴趣的时间点报告体重的患者中，6个月时体重减轻的平均（标准差）百分比为- 13.4% (6.4)(n = 6964)， 12个月时（n = 2050）为- 17.6%(10.2)，18个月时（n = 491）为- 20.3%(11.4)，24个月时（n = 325）为- 20.4%（11.3）。在6个月、12个月、18个月和24个月时，患者体重减轻≥20%的比例分别为13.1%、43.3%、52.5%和50.5%。BMI≥30.0 kg/m2的亚组也有类似的结果。结论：如WeGoTogether项目所报道的，该研究表明，在长期18个月和24个月的随访期间，西马鲁肽治疗显著减轻了体重。这些数据表明，患者在接受西马鲁肽治疗并参加WeGoTogether患者支持计划后，可以在现实环境中实现有临床意义的长期（24个月）体重减轻。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application

Introduction

Semaglutide injection 2.4 mg (Wegovy^®; hereafter referred to as semaglutide) was approved by the US Food and Drug Administration in June 2021 for chronic weight management in adults with overweight or obesity. This study aimed to evaluate the real-world long-term effectiveness of semaglutide in combination with the WeGoTogether patient support program with a follow-up period of up to 24 months.

Methods

This retrospective, noninterventional cohort study included adults with overweight or obesity (body mass index [BMI] ≥ 25.0 kg/m²) who initiated semaglutide and enrolled in WeGoTogether during the study period (6/2021–4/2025). Semaglutide is administered as a once-weekly subcutaneous injection. Patients had ≥ 2 post-index weights, with ≥ 1 weight at 6, 12, 18, and/or 24 months (± 30 days) of follow-up. Self-reported, de-identified data from WeGoTogether were analyzed descriptively. Patient demographics were characterized, and changes in weight and BMI were compared from index to each follow-up time point.

Results

Overall, 8177 patients met the eligibility criteria, including 7604 (93.0%) patients with a BMI ≥ 30.0 kg/m². At baseline, the mean age was 49.5 years, mean weight was 234.1 lb, and mean BMI was 38.4 kg/m²; 83.6% of patients were female. Among patients with reported weight at the time points of interest, the mean (standard deviation) percent weight loss was − 13.4% (6.4) at 6 months (n = 6964), − 17.6% (10.2) at 12 months (n = 2050), − 20.3% (11.4) at 18 months (n = 491), and − 20.4% (11.3) at 24 months (n = 325). The proportions of patients achieving ≥ 20% weight loss were 13.1%, 43.3%, 52.5%, and 50.5% at 6, 12, 18, and 24 months, respectively. Similar results were observed for the subgroup with BMI ≥ 30.0 kg/m².

Conclusion

The study demonstrated substantial weight loss with semaglutide treatment, including over long-term 18- and 24-month follow-up periods, as reported in the WeGoTogether program. These data suggest patients can achieve clinically meaningful long-term (24 months) weight loss in real-world settings when treated with semaglutide and participating in the WeGoTogether patient support program.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.